Abstract: A nuclear device including a plurality of heat pipes; a first fuel configured to surround respective of the plurality of heat pipes coaxially with respect to a central axis of each of the respective heat pipes, the first fuel containing a fissile material at a first enrichment level; a second fuel configured to directly abut the first fuel on the outside of the first fuel and farther than the first fuel from the respective heat pipes surrounded by the first fuel, the second fuel containing the fissile material at a second enrichment level less than the first enrichment level; and a core including the heat pipes arranged in parallel with each other.

Abstract: A nuclear device, including: a heat pipe; a first fuel allocated around a side surface of the heat pipe parallel to a central axis of the heat pipe, the first fuel containing a fissile material at a first concentration; a second fuel allocated on an outer side of the first fuel and containing the fissile material at a second concentration less than the first concentration; and a core including a plurality of the heat pipes arranged in parallel to each of the central axis in the first fuel or in the first fuel and the second fuel.

Abstract: Disclosed herein are compounds, or pharmacologically acceptable salts thereof, having glucokinase activating activity.

Abstract: [Object] To provide a highly safe method for treating diabetes that demonstrates superior effects and is capable of inhibiting adverse side effects. [Means for Solution] A pharmaceutical containing a PPAR? agonist, and a pharmaceutical composition in combination with a biguanide agent and a PPAR? agonist.

Abstract: A pharmaceutical composition containing an FBPase inhibitor and an insulin sensitizer which is 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione or a pharmacologically acceptable salt thereof; and a method for preventing or treating diabetes mellitus by administering the composition to a human.

Abstract: To provide a therapeutic procedure for diabetes mellitus with an excellent efficacy and high safety by possibly reducing side effects. To administer a pharmaceutical composition comprising an FBPase inhibitor at a specified timing.

Abstract: The present invention relates to a pharmaceutical composition containing an FBPase inhibitor as an active ingredient, which is a preventative agent for diabetes mellitus, diabetic complications, hyperlipidemia, hypertension, arteriosclerosis, macroangiopathy, and the like and a therapeutic agent for IGT, and which can safely and easily be administered for a long period.